Irma Febo

Irma Febo

Auto-generated profile, based on publicly available information

Irma Febo

University of Puerto Rico School of Medicine, San Juan, Puerto Rico

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2018 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
CDClemente Diaz
Clemente Diaz
LLLeyi Lin
Leyi Lin
LMLuis J. Martinez
Luis J. Martinez
KEKenneth H. Eckels
Kenneth H. Eckels
MRMaribel Campos Rivera
Maribel Campos Rivera
ASAlexander C. Schmidt
Alexander C. Schmidt
The safety and immunogenicity of four adjuvanted formulations of an investigational tetravalent dengue purified inactivated vaccine (DPIV) were evaluated in a predominantly dengue-primed population in Puerto Rico. In this placebo-controlled, randomized, observer-blind, phase I trial, 100 healthy adults were randomized 1:1:1:1:1 to receive DPIV at Day (D)0 and D28 (1 μg per dengue virus [DENV] type 1–4 adjuvanted with either alum, AS01E or AS03B, or 4 μg per DENV type adjuvanted with alum) or saline placebo. Functional antibody responses were assessed using a microneutralization assay at D56, Month (M)7, and M13. All DPIV formulations were well tolerated and no safety signals were identified through M13. The M13 according-to-protocol (ATP) immunogenicity cohort included 83 participants. The ATP analysis of immunogenicity was performed only on the 78 subjects seropositive for ≥ 1 DENV type at baseline: 69 tetravalent, three trivalent, two bivalent, and four monovalent. In all DPIV groups, geometric mean antibody titers (GMTs) increased from D0 to D56 and waned modestly through M13, while remaining well above prevaccination levels. The 4 μg + alum and the AS01E- and AS03B-adjuvanted formulations were highly immunogenic, with M13-neutralizing antibody GMTs against all four DENV types above 1,000. M13/D0 GMT ratios were highest in the 1 μg + AS03B group (ranging 3.2–3.7 depending on the DENV type). These results encourage continued clinical development of DPIV (ClinicalTrials.gov: NCT01702857).

6 May 2020 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
CDClemente Diaz
Clemente Diaz
MKMichael Koren
Michael Koren
LLLeyi Lin
Leyi Lin
LMLuis J. Martinez
Luis J. Martinez
KEKenneth H. Eckels
Kenneth H. Eckels
Stephen ThomasStephen Thomas
Stephen Thomas
Four formulations of an investigational tetravalent dengue purified inactivated vaccine, administered as two doses one month (M) apart, were previously shown to be immunogenic and well-tolerated up to M13 of the phase I study NCT01702857. Here, we report results of the follow-up from M14 to year (Y) 3. One hundred healthy Puerto Rican adults, predominantly dengue virus (DENV)–primed, were randomized 1:1:1:1:1 to receive placebo or vaccine formulations: 1 μg/serotype/dose adjuvanted with aluminum, AS01E or AS03B, or aluminum-adjuvanted 4 μg/serotype/dose. No serious adverse events occurred. Two medically-attended potential immune-mediated disease cases, vaccination unrelated, were reported (groups 1 µg+Alum and 1 µg+AS03B). Of 14 instances of suspected dengue, none were laboratory confirmed. Geometric mean neutralizing antibody titers against DENV 1-4 waned from M14, but remained above pre-vaccination levels for DENV 1-3, with the highest values for group 1 µg+AS03B: 1220.1, 920.5, 819.4, and 940.5 (Y2), and 1329.3, 1169.2, 1219.8, and 718.9 (Y3). All formulations appeared to be safe and immunogenic during the 3-year follow-up.

9 June 2017 in Journal of Medical Internet Research
Verified
Journal Article
Open access
JBJose Bauermeister
Jose Bauermeister
RGRebecca Giguere
Rebecca Giguere
CLCheng-Shiun Leu
Cheng-Shiun Leu
IFIrma Febo
Irma Febo
RCRoss Cranston
Ross Cranston
ACAlex Carballo-Diéguez
Alex Carballo-Diéguez
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

14 September 2014 in Journal of Adolescent Health
Verified
Journal Article
Closed access
PDF file
CBCherrie B. Boyer
Cherrie B. Boyer
GRGrisel M. Robles-Schrader
Grisel M. Robles-Schrader
SLSu X. Li
Su X. Li
RMRobin L. Miller
Robin L. Miller
JKJames Korelitz
James Korelitz
JEJonathan M. Ellen
Jonathan M. Ellen

GSGeorgina Silva-Suárez
Georgina Silva-Suárez
EBElena Bastida
Elena Bastida
SRSilvia Rabionet
Silvia Rabionet
CBConsuelo M. Beck-Sague
Consuelo M. Beck-Sague
IFIrma Febo
Irma Febo
Carmen D ZorrillaCarmen D Zorrilla
Carmen D Zorrilla
The burden of HIV affects not only HIV-infected patients but also their families and caregivers. It is also known that family support is crucial for people living with HIV. A qualitative study was conducted to explore the life experiences, within the family context, of perinatally HIV-infected (pHIV-I) youth in Puerto Rico. Twenty in-depth interviews were performed and audio-recorded. Within the family context, study participants experienced acceptance, love and support but also stigma and discrimination. They reported that family is an essential component in their lives and treatment. Losing one or both parents at a young age was considered more difficult than having HIV. Most participants who lost their parents lived with other family members. This was a challenging situation for both pHIV-I youth and their caregivers. Participants described their healthcare providers as part of their families and would like to keep in touch as they transition to adult care. Despite the challenges, participants expressed a desire to have children. Services targeted to this population should stress social support, incorporate family members into the medical process, provide special guidance and support while transitioning to adult care, and provide them with the latest information regarding HIV and reproductive options.

1 December 2007
Verified
Journal Article
Closed access
CZCarmen D Zorrilla
Carmen D Zorrilla
VAVivian Tamayo Agrait
Vivian Tamayo Agrait
IFIrma Febo
Irma Febo
LSLydia E Santiago
Lydia E Santiago
CDClemente Díaz
Clemente Díaz
GHGeorge V Hillyer
George V Hillyer